Tag archive for ‘Discovery Laboratories Inc’
Discovery Laboratories: Still Another Delay in the Surfaxin Launch (DSCO, $2.00)
Overview Discovery Laboratories just announced still another delay in the launch of Surfaxin. The Company received five Complete Response letters dating from 2004 before finally gaining approval of Surfaxin in March of 2012. Management then indicated that it planned to launch Surfaxin in November of 2012. However, in October it indicated that there was an […]
Discovery Laboratories: The Surfaxin Launch and Beyond (DSCO, $2.38)
Investment Thesis We are now nearing the long awaited launch of Surfaxin. During the recent conference call on results for 4Q, 2012, the Company reaffirmed that it is anticipating the launch of Surfaxin in 2Q, 2013. The company through a debt deal with Deerfield Capital recently brought in $10 million of cash and will receive […]
Discovery Laboratories: Innovative Financing is a Catalyst to Buy the Stock (DSCO, $2.16)
Investment Perspective Discovery’s (DSCO) stock has languished since it announced before the opening on October 24, 2012 that it was delaying the launch of Surfaxin from November of 2012 until 2Q, 2013. The stock had closed at $2.75 on October 23 and it then closed on October 24 at $2.71. The initial investor reaction appeared […]
Discovery Laboratories Announces Changing of the Guard (DSCO, $2.21)
New Board and New CEO There has been a significant leadership change at Discovery Laboratories (DSCO) which has appointed a new CEO. In addition, changes have also resulted in an almost entirely new five member Board of Directors. Tom Amick has resigned as CEO and has been replaced by John Cooper, who was previously CFO. […]
Discovery Laboratories: Disappointment with the Delay in the Surfaxin Launch Has Created a Buying Opportunity (DSCO, $2.24)
Introduction I had the opportunity to meet with the management of Discovery Laboratories (DSCO) recently and focused on several issues: The problem with one of a number of tests used in quality assurance that was announced in October, 2012 and has delayed introduction from the planned launch of Surfaxin from November, 2012 to 2Q, 2013. […]
Discovery Laboratories: The Street Is Getting on Board With Me
My Recent History on Discovery Laboratories On February 22, 2012, I initiated coverage of Discover Laboratories with a Buy and at a price of $2.82; the report was called Surfaxin Should Be Approved on its March 6th PDUFA Date. I urged investors to buy the stock before the PDUFA date. When I issued the report, […]
Discovery Laboratories: Surfaxin Is Superior to Animal Surfactants (DSCO, $2.74)
Purpose of Report Discovery Laboratories (DSCO) held a quarterly conference call on May 3 to update investors on the pending launch of Surfaxin and Afectair. This followed an important press release the day earlier that discussed a paper presented at the 2012 Pediatric Academies Society Annual Conference in Boston. This report highlights the key points […]
Discovery Laboratories (DSCO): An Update and Buy Re-iteration
I have just published a new report on Discovery Laboratories; this emerging company has two products approved for U.S. marketing with Surfaxin and Afectair and controls worldwide rights to these products with the exception of Surfaxin in Spain and Portugal. It also has a highly promising pipeline. Surfaxin LS is a meaningful improvement over Surfaxin […]
Equity Offering Provides Discovery Laboratories Much Needed Financial Strength (DSCO, $2.81)
Report Summary With a number of cash infusions from a public offering, an ATM drawdown and warrant exercises, Discovery Laboratories (DSCO) has built a strong cash position. There remain a number of possible scenarios for how much more cash will come into the company depending on the exercise of the Green Shoe associated with the […]
Surfaxin Should Be Approved on its March 6th PDUFA Date (DSCO, $2.82)
Investment Thesis and Valuation The transformation of a biotechnology company from development stage to commercial can be the catalyst for a sustained increase in stock price. Discovery Laboratories (DSCO) received regulatory approval for its first product, Afectair, on February 2, 2012 and I believe that there is a strong possibility for approval of a second […]